GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome

By afschroeder • April 25, 2026

Wanner IB, Halford J, Lopez J, Shen S, Chen Y, Zhao H, Salas C, Loo RO, Robicsek S, Ellingson BM, Gornbein J, Van Meter TE, Shaw G, Loo JA, Vespa PM. GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome. Acta Neuropathol Commun. 2026 Apr 24;14(1):101. doi: 10.1186/s40478-026-02240-y. PMID: 42032706; PMCID: PMC13107622.

Tags: Astrocytopathy, Biomarker profiling, Citrullination, DOM STAT, General Internal Medicine, Monitoring, Neurodegeneration, Neurotrauma, Pathomechanism, proteostasis, Publications

Correction: A workshop considering genetic research and data collection with American Indian and Alaska Native people outside of tribal jurisdiction

Beans JA, Blanchard J, Hiratsuka V, Helton T, Carroll S, Dillard D, Orr R, Gachupin FC, Hull S, Haring RC, Garrison NA, Saukeah B, Tsosie[...]

Psychological factors as mediators of the effectiveness of telehealth mindfulness-based interventions for pain and pain-related conditions

Taylor SL, Calvert C, Haley AC, Evans R, Adamowicz J, Allen KD, Bronfort G, Cross LJS, Goldsmith ES, Grant A, Leininger B, Matthias MS, Serpa[...]

Maintaining control: challenges and facilitators to medication adherence among young adults with HIV and recent criminal legal system experience or high risk for system involvement

Mungo L, Harawa NT, Seiden D, McAvoy-Banerjea J, Wang L, Brewer RA, Belzer M. Maintaining control: challenges and facilitators to medication adherence among young adults[...]